Clinical Trials

As clinical trials face strict FDA diversity mandates, Cedar Health Research appoints former SWK Holdings CEO Jody Staggs to scale its community-based network.

As global myopia rates surge, the FDA faces a high-stakes showdown over Sydnexis's SYD-101. The outcome will redefine pediatric eye care and supply chains.

With ophthalmic trial failure rates soaring, a new CRO-led advisory model aims to replace academic vanity boards with operational reality.

Crystalys Therapeutics names Tim Walbert as Chairman, signaling a bold commercial push for its de-risked gout therapy dotinurad as it enters Phase 3 trials.

Ophirex's Phase 2 trial missed its primary goals, but subgroup data and a rare FDA pathway could salvage a game-changing oral snakebite treatment.

Kedrion Biopharma secures Orphan Drug Designation for QIVIGY in Stiff Person Syndrome, leveraging regulatory incentives to build a commercial moat.

With standard-of-care avacopan facing global regulatory withdrawal, InflaRx is stepping into the void. A strategic look at the upcoming Capital Markets Day and the mechanics of clinical resilience.

Matisse Pharmaceuticals secures €14 million to advance a radically different approach to sepsis, targeting cytotoxic histones to stop organ failure.

Fennec Pharmaceuticals unveils compelling trial data showing its therapy prevents permanent hearing loss in children undergoing life-saving chemotherapy.

Kathleen Cook explores how Axsome Therapeutics uses real-world data and novel therapies to solve the hardest problems in modern psychiatric and neurologic care.

The strategic alliance between ProBio and Kun Tuo signals a shift in how global biopharma navigates the fragmented cell and gene therapy clinical landscape.

A breakthrough liquid nitrogen ablation device promises to revolutionize cardiac care, but its maker faces a brutal race against dwindling capital.

Newly independent Ennature Biopharma is betting on validated science for its botanicals, aiming to lead the booming women's health market with transparency.

Trialbee's new AI agent gives patients unprecedented choice in screening, aiming to slash wait times and fix a critical bottleneck in medical research.

After decades of setbacks, a new drug from Skyhawk Therapeutics shows patients not just slowing decline, but improving. Is this the breakthrough a desperate community has been waiting for?

A small biotech assembles top experts to guide a promising, Sanofi-licensed drug through trials, betting it can solve a stubborn cardiovascular challenge.

As pharma giants dominate the obesity space with GLP-1 drugs, Corbus Pharmaceuticals is betting on a different mechanism. Will its upcoming data rewrite the rules?

CSL Seqirus's new flu shot combines three proven technologies. A landmark Lancet study validates its strategic R&D investment in the senior healthcare market.

Starton Therapeutics heads to a key investor conference not with a new molecule, but a new method. Can their delivery tech turn old drugs into new blockbusters?

A €30M investment from the EIB and HERA is backing Ethris's novel mRNA therapeutic. Delivered via nasal spray, it aims to treat chronic respiratory ills and act as a broad-spectrum antiviral.